Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
| 8.17 | |
| 8.22 | |
| - | |
| 8.58 | |
| 7.81 | |
| 6.38-29.7 | |
| 166 M | |
| 20 757 K | |
| 0 | |
| -1.5 | |
| 1.059 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed...
In the current bullish stock market, it’s an exhilarating period for savvy investors betting on the upcoming market sensations. The optimism is connected to the S&P 500 shattering the historic 5000...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
